Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $83.0 million.

  • Ocular Therapeutix's Operating Expenses rose 2269.06% to $83.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $322.0 million, marking a year-over-year increase of 3671.46%. This contributed to the annual value of $322.0 million for FY2025, which is 3671.45% up from last year.
  • Ocular Therapeutix's Operating Expenses amounted to $83.0 million in Q4 2025, which was up 2269.06% from $83.2 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Operating Expenses ranged from a high of $83.2 million in Q3 2025 and a low of $27.6 million during Q1 2021
  • For the 5-year period, Ocular Therapeutix's Operating Expenses averaged around $47.5 million, with its median value being $35.3 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 72.93% in 2022, then skyrocketed by 9413.5% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Operating Expenses (Quarter) stood at $30.4 million in 2021, then rose by 10.14% to $33.4 million in 2022, then grew by 4.23% to $34.9 million in 2023, then surged by 94.14% to $67.7 million in 2024, then rose by 22.69% to $83.0 million in 2025.
  • Its last three reported values are $83.0 million in Q4 2025, $83.2 million for Q3 2025, and $81.1 million during Q2 2025.